EGFR and cancer: Compounds that utilize both non-covalent interactions and thiol-reactive mechanisms for target recognition have led to innovative approaches in the development of TKIs for cancer therapy, targeting proteins such as JAK3 [160], BTK, [161,162], and EGFR [163,164].